8-methylguanosine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 135463489 |
| SCHEMBL ID | 483237 |
| MeSH ID | M0299741 |
| Synonym |
|---|
| 36799-17-4 |
| SCHEMBL483237 |
| DTXSID00576674 |
| 8-methylguanosine |
| monomethylguanosine |
| 2-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-8-methyl-1h-purin-6(9h)-one |
| 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-methyl-1h-purin-6-one |
| 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-methyl-6,9-dihydro-1h-purin-6-one |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (1.59) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 11 (17.46) | 29.6817 |
| 2010's | 16 (25.40) | 24.3611 |
| 2020's | 33 (52.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (3.08%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 63 (96.92%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder | 2.03 | 1 | 0 | pyrimidine nucleobase; pyrimidone | allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite |
| carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. | 2.08 | 1 | 0 | N-nitrosoureas; organochlorine compound | alkylating agent; antineoplastic agent |
| temozolomide [no description available] | 2.08 | 1 | 0 | imidazotetrazine; monocarboxylic acid amide; triazene derivative | alkylating agent; antineoplastic agent; prodrug |
| thymidine [no description available] | 2 | 1 | 0 | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite |
| uridine [no description available] | 3.55 | 2 | 0 | uridines | drug metabolite; fundamental metabolite; human metabolite |
| cytidine [no description available] | 2.21 | 1 | 0 | cytidines | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| tert-butylhydroperoxide tert-Butylhydroperoxide: A direct-acting oxidative stress-inducing agent used to examine the effects of oxidant stress on Ca(2+)-dependent signal transduction in vascular endothelial cells. It is also used as a catalyst in polymerization reactions and to introduce peroxy groups into organic molecules.. tert-butyl hydroperoxide : An alkyl hydroperoxide in which the alkyl group is tert-butyl. It is widely used in a variety of oxidation processes. | 2 | 1 | 0 | alkyl hydroperoxide | antibacterial agent; oxidising agent |
| trichloroacetic acid Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine. | 2.11 | 1 | 0 | monocarboxylic acid; organochlorine compound | carcinogenic agent; metabolite; mouse metabolite |
| pseudouridine [no description available] | 3.31 | 1 | 0 | pseudouridines | fundamental metabolite |
| 1-methyladenosine [no description available] | 3.31 | 1 | 0 | methyladenosine | human metabolite |
| adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | 4.01 | 3 | 0 | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
| 5-methylcytosine 5-Methylcytosine: A methylated nucleotide base found in eukaryotic DNA. In ANIMALS, the DNA METHYLATION of CYTOSINE to form 5-methylcytosine is found primarily in the palindromic sequence CpG. In PLANTS, the methylated sequence is CpNpGp, where N can be any base.. 5-methylcytosine : A pyrimidine that is a derivative of cytosine, having a methyl group at the 5-position. | 3.31 | 1 | 0 | methylcytosine; pyrimidines | human metabolite |
| methylthymidine methylthymidine: RN given refers to N-3-methylthymidine | 2 | 1 | 0 | ||
| 1-methylinosine 1-methylinosine : Inosine carrying a methyl substituent at position 1 on the hypoxanthine ring. | 1.96 | 1 | 0 | inosines | metabolite |
| phosphoramidic acid phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds | 2.05 | 1 | 0 | phosphoric acid derivative | |
| 5,6-dihydrouridine dihydrouridine : The uridine derivative obtained by formal hydrogenation of the endocyclic double bond in the uracil ring. | 3.31 | 1 | 0 | uridines | biomarker |
| n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase. | 2.21 | 1 | 0 | methyladenosine | |
| n-acetylcytidine N(4)-acetylcytidine : Cytidine in which one of the exocyclic amino hydrogens is substituted by an acetyl group. | 2.21 | 1 | 0 | acetamides; cytidines; secondary carboxamide | metabolite |
| wye [no description available] | 2 | 1 | 0 | ||
| 5-formylcytidine 5-formylcytidine: found at the first position of the anticodon of methionine tRNA from bovine liver mitochondria; structure given in first source | 2.21 | 1 | 0 | ||
| 2'-o-methylcytidine [no description available] | 2.21 | 1 | 0 | methylcytidine | |
| thiophosphoric acid thiophosphoric acid: RN given refers to parent cpd | 2.5 | 2 | 0 | phosphorothioic acid | |
| glycosides [no description available] | 2.21 | 1 | 0 | ||
| phenyl-n-tert-butylnitrone phenyl-N-tert-butylnitrone: a spin-trapping agent | 2 | 1 | 0 | ||
| oligonucleotides [no description available] | 2.01 | 1 | 0 | ||
| deoxyguanosine [no description available] | 2.25 | 1 | 0 | purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| guanosine monophosphate Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase. | 2.11 | 1 | 0 | guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate | biomarker; Escherichia coli metabolite; metabolite; mouse metabolite |
| guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. | 2.11 | 1 | 0 | guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor |
| guanine [no description available] | 2.73 | 3 | 0 | 2-aminopurines; oxopurine; purine nucleobase | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose. | 6.97 | 51 | 0 | guanosines; purines D-ribonucleoside | fundamental metabolite |
| inosine [no description available] | 1.96 | 1 | 0 | inosines; purines D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| 7-methylguanine 7-methylguanine: RN given refers to unlabeled cpd; structure. 7-methylguanine : A methylguanine that is guanine substituted by a methyl group at position 7. It is a metabolite obtained during the methylation of DNA.. 2-imino-7-methyl-1,2,3,7-tetrahydro-6H-purin-6-one : A 7-methylguanine that is 1,2,3,7-tetrahydro-6H-purin-6-one substituted by an imino group at position 2 and a methyl group at position 7.. 2-amino-7-methyl-7H-purin-6-ol : A 7-methylguanine that is 7H-purine substituted by an amino group at position 2, a methyl group at position 7 and a hydroxy group at position 6.. 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one : A 7-methylguanine that is 1,7-dihydro-6H-purin-6-one substituted by an amino group at position 2 and a methyl group at position 7. | 2.25 | 1 | 0 | 7-methylguanine | |
| dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration. | 2.08 | 1 | 0 | dacarbazine | |
| 2'-o-methylguanosine 2'-O-methylguanosine : Guanosine with the hydrogen on the hydroxyl at position C-2' substituted with a methyl group. | 2.21 | 1 | 0 | methylguanosine | metabolite |
| 8-hydroxyguanosine 8-hydroxyguanosine: immunostimulant for B lymphocytes; structure given in first source | 1.99 | 1 | 0 | purine nucleoside | |
| 7-methylguanosine 7-methylguanosine : A positively charged methylguanosine in which a single methyl substituent is located at position 7. | 3.01 | 4 | 0 | methylguanosine; organic cation | metabolite |
| n(2),n(2)-dimethylguanosine N(2),N(2)-dimethylguanosine: elevated levels in urine of cancer patients. N(2),N(2)-dimethylguanosine : A guanosine where the hydrogens of the amine group at C-2 are substituted by methyl groups. | 1.96 | 1 | 0 | methylguanosine | human metabolite |
| idx184 IDX184: prodrug to enhance formation in the liver of the active triphosphate of 2'-methylguanosine, a potent and specific polymerase inhibitor of the hepatitis C virus; structure in first source | 2.11 | 1 | 0 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Anoxemia [description not available] | 0 | 2.41 | 1 | 0 |
| Pulmonary Hypertension [description not available] | 0 | 2.41 | 1 | 0 |
| Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms. | 0 | 2.41 | 1 | 0 |
| Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. | 0 | 2.41 | 1 | 0 |
| Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years. | 0 | 2.82 | 2 | 0 |
| Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer. | 0 | 2.6 | 1 | 0 |
| Cancer of Esophagus [description not available] | 0 | 2.6 | 1 | 0 |
| Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. | 0 | 2.6 | 1 | 0 |
| Benign Neoplasms [description not available] | 0 | 4.25 | 4 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 4.25 | 4 | 0 |
| Cancer of the Thyroid [description not available] | 0 | 2.41 | 1 | 0 |
| Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. | 0 | 2.41 | 1 | 0 |
| Microsatellite Instability The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR. | 0 | 2.41 | 1 | 0 |
| Cancer of Stomach [description not available] | 0 | 2.41 | 1 | 0 |
| Stomach Neoplasms Tumors or cancer of the STOMACH. | 0 | 2.41 | 1 | 0 |
| Lung Adenocarcinoma [description not available] | 0 | 2.6 | 1 | 0 |
| Cancer of Lung [description not available] | 0 | 2.6 | 1 | 0 |
| Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. | 0 | 2.6 | 1 | 0 |
| Lung Neoplasms Tumors or cancer of the LUNG. | 0 | 2.6 | 1 | 0 |
| Hepatocellular Carcinoma [description not available] | 0 | 3.22 | 3 | 0 |
| Cancer of Liver [description not available] | 0 | 3.22 | 3 | 0 |
| Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. | 0 | 3.22 | 3 | 0 |
| Liver Neoplasms Tumors or cancer of the LIVER. | 0 | 3.22 | 3 | 0 |
| Adenocarcinoma, Basal Cell [description not available] | 0 | 2.6 | 1 | 0 |
| Cancer of Prostate [description not available] | 0 | 2.6 | 1 | 0 |
| Adenocarcinoma A malignant epithelial tumor with a glandular organization. | 0 | 2.6 | 1 | 0 |
| Prostatic Neoplasms Tumors or cancer of the PROSTATE. | 0 | 2.6 | 1 | 0 |
| Malignant Melanoma [description not available] | 0 | 2.6 | 1 | 0 |
| Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) | 0 | 2.6 | 1 | 0 |
| Uveal Neoplasms Tumors or cancer of the UVEA. | 0 | 2.6 | 1 | 0 |
| Sarcoma, Epithelioid [description not available] | 0 | 2.6 | 1 | 0 |
| Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. | 0 | 2.6 | 1 | 0 |
| Acute Myelogenous Leukemia [description not available] | 0 | 2.98 | 3 | 0 |
| Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. | 0 | 2.98 | 3 | 0 |
| Breast Cancer [description not available] | 0 | 2.76 | 2 | 0 |
| Breast Neoplasms Tumors or cancer of the human BREAST. | 0 | 2.76 | 2 | 0 |
| Adenocarcinoma Of Kidney [description not available] | 0 | 2.6 | 1 | 0 |
| Cancer of Kidney [description not available] | 0 | 2.6 | 1 | 0 |
| Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. | 0 | 2.6 | 1 | 0 |
| Kidney Neoplasms Tumors or cancers of the KIDNEY. | 0 | 2.6 | 1 | 0 |
| Congenital Zika Syndrome [description not available] | 0 | 2.25 | 1 | 0 |
| Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME. | 0 | 2.25 | 1 | 0 |
| Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) | 0 | 2.25 | 1 | 0 |
| Deficiency, Mental [description not available] | 0 | 2.15 | 1 | 0 |
| Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) | 0 | 2.15 | 1 | 0 |
| Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. | 0 | 2.08 | 1 | 0 |
| Benign Neoplasms, Brain [description not available] | 0 | 2.08 | 1 | 0 |
| Astrocytoma, Grade IV [description not available] | 0 | 2.08 | 1 | 0 |
| Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. | 0 | 2.08 | 1 | 0 |
| Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. | 0 | 2.08 | 1 | 0 |
| Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available] | 0 | 2.48 | 2 | 0 |
| Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. | 0 | 2.48 | 2 | 0 |
| B16 Melanoma [description not available] | 0 | 1.99 | 1 | 0 |
| Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) | 0 | 2 | 1 | 0 |